Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2067 - Apatinib combined with irinotecan in treatment of recurrent high-grade gliomas (127P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Cytotoxic Therapy;  Central Nervous System Malignancies

Presenters

Xiaodong Jiang

Citation

Annals of Oncology (2017) 28 (suppl_10): x35-x38. 10.1093/annonc/mdx657

Authors

X. Jiang, L. Wang, T. Yang, Y. Xia, Y. Qiao

Author affiliations

  • Medical Oncology, 1st People's Hospital of Lianyungang, 222002 - Lianyungang/CN
More

Resources

Abstract 2067

Background

High-grade gliomas (HGGs) are the most common and aggressive group of primary central nervous system (CNS) tumors. They are characterized by diffuse parenchymal infiltration and prominent angiogenesis. Apatinib is a novel inhibitor of VEGFR-2, which was admitted for the treatment of advanced gastric cancer patients who had failed after the second-line and above treatment. However, there have been no reports for treating recurrent high-grade gliomas with this drug.

Methods

This was a single-arm, open-label, exploratory study design. Eligibility criteria included histologically proven glioma, patient age 18-75 years. A history of receiving previous treatment was not required. All the patients were orally given apatinib at an initial dose of 500-850 mg (qd) and irinotecan (125 mg/m2) on days 1, 8 of each 21-day cycle. After 6 cycles, patients were treated with apatinib 500-850 mg (qd) until disease progression or death.

Results

A total of 10 patients including 7 males and 3 females were eligible. The median age was 49 years (range 27-66 years). Among the 10 patients, 9 were available for the efficacy evaluation. Two patients achieved partial response (PR), 3 had stable disease (SD), and 4 had progressive disease (PD). The objective response rate (ORR) and the disease control rate (DCR) were 22.22% (2/9) and 55.56% (5/9), respectively. All patients were included for safety analysis. The incidence of adverse events (AEs) was 100%. The common AEs were bone marrow suppression (50%) and hypertension (40%), gastrointestinal reaction (30%), diarrhoea (30%) and sinus rhythm (20%).

Conclusions

Apatinib combined with irinotecan is an active regimen for patients with recurrent high-grade gliomas with a comparable disease control and tolerable adverse reactions.

Clinical trial identification

None

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.